Cost-effectiveness Analysis of Reference Infliximab (Remicade) Compared to its Biosimilar (Remsima) in Iraqi Patients with Rheumatoid Arthritis (Conference Paper )#
DOI:
https://doi.org/10.31351/vol31issSuppl.pp100-110Keywords:
Cost-effectiveness, Rheumatoid arthritis, Infliximab, Biosimilar, Biological medicine, Quality of life, Iraq, PharmacoeconomicsAbstract
The study objective was to conduct Pharmacoeconomics study (cost-effective analysis) between infliximab reference (Remicade) and its biosimilar (Remsima) in patients with rheumatoid arthritis (RA) in Iraqi hospitals.
This is a retrospective multicenter pharmacoeconomic analysis conducted at two large teaching governmental hospitals in Baghdad, Iraq which provided infliximab to patients with RA. Data were collected from patient’s medical records and face-to-face interviews with the patients from December 2021 to April 2022.
The study included 57 patients with rheumatoid arthritis (RA). The patients were categorized into two groups according to the type of infliximab they received over 30 weeks: 27 patients received reference infliximab (Remicade) and 30 patients received biosimilar infliximab (Remsima). The two groups had comparable demographic and baseline disease parameters, with a mean age of 49.6 years and a BMI of 30.0. The vast majority of participants were women (82.5%) with low level of formal education (65%). Overall, both infliximab biopharmaceuticals had good effectiveness to reduce the RA disease activity (CDAI) and improve patient quality of life. They both had comparable adverse reactions including UTI, fatigue, and headache. There was no significant difference (P-value >0.05) in disease activity between the two groups according to RA clinical disease activity index (CDAI) score across all three-time measures: before biological therapy, 14 weeks post-therapy and 30 weeks post-therapy.
In 2019, Remicade was slightly more effective and provide better quality of life, but costlier ($41,896 per QALY) compared to Remsima. It was not clear whether the reference biologic (Remicade) or its biosimilar (Remsima) was more cost effective. In 2021, Remicade was more cost effective compared to Remsima because Remicade was less expensive and relatively more effective according to CDAI and EQ-5D-5L scores. Registering and purchasing both reference infliximab and its biosimilar was good idea to keep the competition in the price and maintain infliximab for RA patients.
References
Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Prim. 2018 Feb 8;4.
Önnheim K, Huang S, Strid Holmertz A, Andersson S, Lönnblom E, Jonsson C, et al. Rheumatoid arthritis chondrocytes produce increased levels of pro-inflammatory proteins. Osteoarthr Cartil Open. 2022 Mar 1;4(1):100235.
Tanaka Y. Rheumatoid arthritis. 2020;
Canadian Agency for Drugs and Technologies in Health. Golimumab (Simponi) IV: In Combination with Methotrexate (MTX) for the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis. Golimumab IV Comb with Methotrexate Treat Adult Patients with Moderately to Sev Act Rheum Arthritis [Internet]. 2015 [cited 2022 May 17]; Available from: https://www. ncbi.nlm.nih.gov/books/NBK349383/?report=reader%0Ahttp://www.ncbi.nlm.nih.gov/pubmed/26962595.
Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int [Internet]. 2021;41(5):863–77. Available from: https://doi.org/10.1007/s00296-020-04731-0
Al Rawi ZS, Alazzawi AJ, Alajili FM, Alwakil R. Rheumatoid arthritis in population samples in Iraq. Ann Rheum Dis. 1978;37(1):73–5.
Alkazzaz A. Incdence of Rheumatoid Arthritis [ 2001 to 2011 ]. Iraqi Postgrad Med J. 2013;12(4):568–72.
Chen CI, Wang L, Wei W, Yuce H, Phillips K. Burden of rheumatoid arthritis among US Medicare population: Co-morbidities, health-care resource utilization and costs. Rheumatol Adv Pract. 2018;2(1):i1–9.
Lau CS, Chia F, Harrison A, Hsieh TY, Jain R, Jung SM, et al. APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis. 2015 Sep 1;18(7):685–713.
Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):S685–99.
Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77(2):165–74.
Kuek A, Hazleman BL, Östör AJK. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: A medical revolution. Vol. 83, Postgraduate Medical Journal. 2007. p. 251–60.
Nast A, Mrowietz U, Kragballe K, De Jong EMGJ, Puig L, Reich K, et al. Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis-A multinational cross-sectional study. Arch Dermatol Res. 2013 Dec 1;305(10):899–907.
Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014 Jan 1;73(1):198–206.
Knezevic I, Griffiths E. WHO standards for biotherapeutics, including biosimilars: an example of the evaluation of complex biological products. Ann N Y Acad Sci [Internet]. 2017 Nov [cited 2022 Jun 9];1407(1):5–16. Available from: https:// onlinelibrary.wiley.com/doi/10.1111/nyas.13434
England BR, Tiong BK, Bergman MJ, Curtis JR, Kazi S, Mikuls TR, et al. 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. Arthritis Care Res. 2019 Dec 1;71(12):1540–55.
Blair HA, Deeks ED. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases. BioDrugs. 2016 Oct 1;30(5):469–80.
Al-Jumaili AA, Younus MM, Kannan YJA, Nooruldeen ZE, Al-Nuseirat A. Pharmaceutical regulations in iraq: From medicine approval to postmarketing. East Mediterr Heal J. 2021 Oct 1;27(10):1007–15.
Al Ani NA, Gorial FI, Al-Sulaitti S, Humadi JA, Awadh NI, Mounir M, et al. Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq. Vol. 11, Open Access Rheumatology: Research and Reviews. Dove Medical Press Ltd; 2019.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.
Remicade 100mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) [Internet]. [cited 2022 Sep 13]. Available from: https:// www. medicines. org.uk/ emc/ product/3831/smpc
Remsima 100 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) [Internet]. [cited 2022 Sep 13]. Available from: https:// www. Medicines .org .uk/ emc/ product/3709/smpc
Van Der Heijde DMFM, Van ’t Hof M, Van Riel PLCM, Van De Putte LBA. Development of a disease activity score based on judgement in clinical practice by rheumatologists. In: Journal of Rheumatology. J Rheumatol; 1993. p. 579–81.
Singh H, Kumar H, Handa R, Talapatra P, Ray S, Gupta V. Use of Clinical Disease Activity Index Score for Assessment of Disease Activity in Rheumatoid Arthritis Patients: An Indian Experience. Arthritis. 2011 Dec 29;2011:1–5.
EuroQol Research Foundation. EQ-5D-5L User Guide. 2019.
26. Van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Heal. 2012 Jul;15(5):708–15.
Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis [Internet]. 1987 [cited 2022 Sep 11];40(6):593–600. Available from: https:// pubmed. ncbi. nlm. nih.gov/3298297/
Kimadia | Homepage [Internet]. [cited 2022 Jun 19]. Available from: https:// kimadia .iq/ en/ article/ view/34
Sjöström M, Lindholm L, Samuelsson E. Mobile app for treatment of stress urinary incontinence: A cost-effectiveness analysis. J Med Internet Res. 2017;19(5).
Gerosa M, De Angelis V, Riboldi P, Meroni P. Rheumatoid Arthritis: A Female Challenge. Women’s Heal [Internet]. 2008 Mar 1 [cited 2022 Jul 12];4(2):195–201. Available from: http:// journals .sagepub. com /doi /10.2217 /17455057.4.2.195
Feng X, Xu X, Shi Y, Liu X, Liu H, Hou H, et al. Body Mass Index and the Risk of Rheumatoid Arthritis: An Updated Dose-Response Meta-Analysis. Vol. 2019, BioMed Research International. Hindawi Limited; 2019.
Cohen SB, Alten R, Kameda H, Hala T, Radominski SC, Rehman MI, et al. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Res Ther. 2018 Jul 27;20(1).
Al-Jumaili AA, Fahmi HL. Understanding the Experience of Hospital Pharmacists with the Effectiveness, Safety, Adverse Drug Reaction Reporting and Interchangeability of Biopharmaceutical Medicines. Iraqi J Pharm Sci. 2022;31(1):72–86.
Detert J, Klaus P. Biologic monotherapy in the treatment of rheumatoid arthritis. Biologics [Internet]. 2015 [cited 2022 Sep 13];9:35. Available from: /pmc/articles/PMC4440355/
Jørgensen TS, Turesson C, Kapetanovic M, Englund M, Turkiewicz A, Christensen R, et al. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry. PLoS One. 2017;12(2):1–16.
Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther [Internet]. 2016;18(1):1–12. Available from: http://dx.doi.org/10.1186/s13075-016-0981-6
Rosa-Gonçalves D, Bernardes M, Costa L. Quality of life and functional capacity in patients with rheumatoid arthritis – Cross-sectional study. Reumatol Clin. 2018 Nov 1;14(6):360–6.
World Bank Group - International Development, Poverty, & Sustainability [Internet]. [cited 2022 Jul 12]. Available from: https://www.worldbank.org/en/home.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)
This work is licensed under a Creative Commons Attribution 4.0 International License.
